ArticleBMJ open2025
Evaluation of a novel approach for colorectal cancer screening using an intelligent tool (INTEL-PATH CRC): a protocol for a multicentre, real-world, cohort study.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTraditional colorectal cancer (CRC) screening programmes in China face two major challenges: low screening coverage and poor adherence. Mobile health shows promise for cancer prevention, and a WeChat-based intelligent tool has been developed to support full-cycle CRC screening, including risk assessment, individualised screening recommendation, appointment management, result processing and health education. This study aims to evaluate the feasibility and effectiveness of this tool-based screening strategy in a multicentre, prospective cohort. METHODS AND ANALYSIS: 10 000 eligible participants aged 45-74 years will be enrolled from five provinces in China. After signing informed consent, participants need to complete an online questionnaire based on the modified and widely validated Asia-Pacific Colorectal Screening score. A score of ≥4 indicates high risk; otherwise, participants are classified as low or intermediate risk. For high-risk individuals, colonoscopy is recommended as the primary screening method, with faecal immunochemical test (FIT) as an alternative. For those at low or intermediate risk, FIT is recommended, followed by diagnostic colonoscopy for those who test positive. The primary outcomes are the detection rate of advanced colorectal neoplasia, compliance rates and detection rate of any colorectal adenoma at baseline screening. Final diagnoses are based on colonoscopy and pathology results. The secondary outcomes include CRC incidence and mortality, which will be assessed through passive follow-up over at least 10 years using linkage to cancer registry and death surveillance databases. ETHICS AND DISSEMINATION: The programme was approved by the Ethics Committee of the National Cancer Center/Cancer Hospital, the Chinese Academy of Medical Sciences and Peking Union Medical College (23/220-3962). Expected outcomes will be disseminated through research reports, peer-reviewed papers, conference and patents. TRIAL REGISTRATION NUMBER: ChiCTR2400086754.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.